Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study

“…Luseogliflozin added to liraglutide significantly reduced bodyweight over a period of 52 weeks (−2.71 kg at week 52), similar to the results of a luseogliflozin monotherapy study (−2.68 kg at week 52), indicating that luseogliflozin caused a similar bodyweight reduction despite the ≥12‐week liraglutide pretreatment before luseogliflozin administration. The extent of the weight loss effects of luseogliflozin and liraglutide have been reported to depend on baseline BMI.…”

Factors associated with treatment satisfaction in patients with type 2 diabetes mellitus using oral glucose-lowering agents: a cross-sectional study in urban districts in Japan

“…It is, therefore, possible that the results of the study may not be applicable to younger patients, those patients with less education, poor glycemic control or those with severe complications. However, we think the association between use of SGLT2i and satisfaction would be found even in younger patients and those with poorer glycemic control because the effects of SGLT2i were also found in those patients [13]. Anyway, another study of a heterogeneous group of patients with regard to background parameters and clinical complications is needed to clarify this issue.…”

Use of sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations

“…Table S1 summarizes the antihyperglycaemic effects of SGLT‐2 inhibitors as a monotherapy or in combination with other GLDs or insulin in Asian patients with T2DM. In placebo‐controlled trials (duration up to 24 weeks) on treatment‐naïve Asian patients with T2DM, SGLT‐2 inhibitor monotherapy reduced the HbA1c level by up to −1.11% from baseline, with a greater reduction observed in patients with high baseline HbA1c levels . In Asian patients with uncontrolled T2DM, SGLT‐2 inhibitors as add‐on therapy to other GLDs further reduced HbA1c, ranging from −0.44% to −1.26% (study duration up to 52 weeks) .…”

“…Apart from HbA1c, indices of insulin resistance and hyperinsulinaemia are associated with impaired myocardial contractility, cardiac hypertrophy and atherosclerosis; an association of postprandial hyperglycaemia with oxidative stress and endothelial dysfunction has also been reported . In Asian patients with T2DM, SGLT‐2 inhibitors alone or in combination with oral GLDs improved insulin sensitivity and β‐cell function, reduced insulin and proinsulin levels, and decreased postprandial glucose levels …”